Background: The biochemical response to ursodeoxycholic acid (UDCA) -so-called 'treatment
Events were defined to reflect ESLD requiring LT, as follows: (1) death from a liver-related cause, meaning liver failure, variceal haemorrhage or hepatocellular carcinoma (HCC); (2) LT for PBC, or (3) for participants who were still alive and had never undergone LT, serum bilirubin measuring ≥100μmol/L for the first time. We considered LT for PBC to be an acceptable surrogate for liver- Supplementary Figure S1 ) (12) . Furthermore, we selected the threshold, bilirubin ≥100μmol/L, because bilirubin at this level is widely accepted to be an indication for LT, as reported in the EASL guidelines on the management of cholestatic liver diseases, 2009 (1) .
Participants who did not reach an event were censored at the date of their most recent blood tests or the date of non-liver related death, if applicable.
Explanatory variables
We considered variables for inclusion in the risk score that were clinically relevant or had been shown in at least one previous study to predict survival in PBC. These variables were as follows:
• Age at diagnosis;
• Sex;
• Year of diagnosis;
• Blood tests at the time of diagnosis, i.e. serum sodium, creatinine, bilirubin (BIL), alanine • Spleen size and the presence of ascites by ultrasound scan at the time of diagnosis;
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• Treatment with UDCA (yes or no);
• Liver biochemistry after 12 months of treatment with UDCA. i.e. BIL12, ALT12, AST12 and ALP12.
To account for inter-operator variability in the measurement of laboratory investigations, research nurses were asked to provide the reference range reported for each laboratory investigation, as well as the result and date of the test. In our analysis, the creatinine, BIL, ALT, AST, ALP and immunoglobulins were treated as multiples of their respective upper reference levels. The sodium, albumin and platelet count were treated as multiples of their respective lower reference levels.
Measurements for both AST and ALT were available for comparatively few subjects (n=586, 14.6%) reflecting variation in biochemistry laboratory practice across the UK. We therefore defined a variable, transaminases (TA) that was the ALT where this was available, otherwise the AST. Likewise, measurements for both PT and INR were available for comparatively few patients (n=897, 21.4%).
Where the INR was missing, we estimated the INR to be the ratio of the PT to the mean normal prothrombin time, calculated as the mean of the upper and lower reference level in that hospital.
Treatment with UDCA was included as a dichotomous explanatory variable (i.e. any treatment or no treatment). We did not account for the baseline, weight-adjusted dose of UDCA because these data were not available. However, we identified a subgroup of participants for whom the current weightadjusted dose of UDCA was available (n = 1,253). In this subgroup, the median dose of UDCA was 12 mg/kg/day (IQR 9 -14 mg/kg/day). This is lower than the recommended dose of UDCA (13) (14) (15) mg/kg/day), albeit comparable to the median dose reported by Lammers et al. (13) in their study of 4,845 PBC patients from leading academic centres across the globe. Notably, we found that the vast majority of participants taking UDCA <13 mg/kg/day fulfilled the Paris I definition of treatment response, suggesting they were receiving an individually effective dose (Supplementary Figure S2) .
For this reason, we did not consider that failing to account for weight-adjusted dose of UDCA would substantially bias our analysis.
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Derivation of PBC risk scores
For the derivation and the validation of the risk scores we excluded participants confirmed to have another chronic liver disease in addition to PBC. We also excluded participants with PBCautoimmune hepatitis (AIH) overlap syndrome, defined as interface hepatitis on liver histology combined with TA≥5×ULN or IgG≥2×ULN, over-and-above features of PBC (14) . Finally, we excluded participants who had never received UDCA; had received <12 months of treatment with UDCA, or had discontinued UDCA prematurely for any reason other than death or LT.This left a cohort of participants with pure PBC who had received ongoing treatment with UDCA for at least 12 months.
Following convention (15, 16) we randomly allocated 60% of these UDCA-treated participants to a derivation cohort and the remaining 40% to a validation cohort.
Within the derivation cohort, we undertook multiple imputation using chained equations (20 imputations) to account for missing values; as well as the predictor variables, the imputation model also included the binary event/censoring variable and Nelson-Aalen estimate of cumulative hazard (17) . We performed univariate analysis of 20 variables (listed in Table 1 ) using Cox proportional hazards regression. Variables that were statistically significant at P = 0.05 in univariate analysis were included in a multivariable Cox model. Non-automatic backward selection was employed to identify the best fitting model, adjusting for age and calendar year at diagnosis in each iteration of model reduction. The multivariable fractional polynomial (mfp) procedure in Stata was used to identify the most appropriate functional form for each of the variables included in the best-fitting model. The coefficients were combined with the baseline survivor functions estimated from the model to derive three separate equations predicting the risk of an event occurring within 5, 10 or 15 years of baseline, respectively. Hereafter we refer to these equations as the 5, 10 and 15-year risk scores.
Validation of the PBC risk score
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We applied the 5, 10 and 15-year risk scores to participants in the validation cohort. To assess discrimination, we calculated the area under receiver operating characteristic curve (AUC) for each risk score. To assess calibration, we compared the observed versus predicted risk of an event occurring within 5, 10 or 15 years across each decile of the 5, 10 and 15-year risk scores, respectively. For comparison, we also assessed the discrimination of the Paris 1, Barcelona, Paris 2 and Toronto models at 5, 10 and 15 years using the AUC.
To assess the accuracy of the risk scores for measurement of risk prior to treatment, we calculated the 5,10 and 15-year risk scores in a group of participants who had never been established on UDCA and had been followed-up for at least 12 months, using the baseline BIL, TA and ALP instead of the equivalent measurements on treatment. We then calculated the respective AUCs. To assess the accuracy of the risk scores using the ALT12 rather than TA12, we calculated the 5, 10 and 15-year risk scores using the ALT12 for all participants in the validation cohort for whom this measurement was available. We then calculated the respective AUCs. Likewise, to assess the accuracy of the risk scores using the AST12 rather than TA12, we calculated each risk score using the AST12 for all participants in the validation cohort for whom this measurement was available, then calculated the respective AUCs.
All analyses were performed using Stata version 13.0 (StataCorp, Texas 77845 USA).
Results
Cohort characteristics
A total of 4099 patients with PBC were recruited to the cohort up to 31 st July 2015. Of these, 77 were confirmed to have PBC-AIH overlap syndrome or another liver disease in addition to PBC; these participants were excluded from further analysis. Of those remaining, we excluded 857 participants who had never received UDCA; had received <12 months of treatment with UDCA, or had discontinued UDCA prematurely. This left 3165 UDCA-treated participants, whom we included in the analysis.
In these UDCA-treated participants, the year of diagnosis of PBC ranged from 1974-2014 These UDCA-treated participants were randomly allocated to a derivation cohort consisting of 1,916
participants or validation cohort consisting of 1,249 participants. The baseline characteristics of participants in the derivation and validation cohorts are shown in Table 1 ; the cohorts were similar, as expected from random allocation. Consistent with other recent series (7, 18, 19) , approximately 10% of participants had advanced disease at diagnosis (exemplified here by splenomegaly or ascites) and approximately 20% of participants were ANA positive. Complete information about explanatory variables was available for 1,460 participants (76%) in the derivation cohort and for 959 participants (77%) in the validation cohort. Information on outcome was available for all participants. The rate of missing information for each variable is shown in Supplementary Table S1 .
Derivation of a PBC risk score
In univariate analysis, age at diagnosis, calendar year at diagnosis, Na, BIL, TA, ALP, albumin, platelets, IgG, ANA, splenomegaly, ascites, BIL12, ALP12 and TA12 were associated with outcome and were taken forward for multivariable modelling. Following non-automatic backward selection, the best fitting Cox model included five variables: albumin, platelet, BIL12, TA12 and ALP12, with a
Harrell's c statistic of 0.92 ( Table 2) . Each iteration of the multivariable model was adjusted for age and calendar year at diagnosis but these variables did not significantly improve the fit and were excluded from the final model (data not shown). A total of 754 participants had never been established on UDCA and had been followed-up for at least 12 months. In this subgroup of untreated participants, the median follow-up was 6.65 years (IQR, 3.5 -10.6 years); total follow-up was 5,646 patient-years, and 201 (26.7%) suffered an event.
The risk scores applied to this subgroup using the baseline BIL, TA and ALP (instead of the equivalent measurements after 12 months of treatment) had high discrimination, the AUC being 0. 
Discussion
We analysed data from more than 3,000 participants in the UK-PBC Research Cohort to develop and validate a scoring system for long-term prediction of ESLD. The scoring system incorporates readily available and objective laboratory measures, i.e. the baseline platelet count and serum albumin, and the serum bilirubin, transaminases and ALP measured after twelve months of treatment with UDCA.
The scoring system is proposed to facilitate management of PBC in clinical practice.
In the current study, we confirmed that existing long-term prognostic models of PBC are accurate, A major advantage of our scoring system is that it provides accurate, individualised estimates of the risk of developing ESLD within defined time points in the future. This contrasts with existing longterm prognostic models that dichotomise patients into treatment responders or non-responders, at low or high risk of developing ESLD at an unknown point in the future (Supplementary Figure S4) . In clinical practice, the scoring system should be most useful to identify patients who would obtain greatest benefit from further risk-reduction using second-line therapy. This is especially pertinent in PBC, with second-line agents currently in development (20). However, it should also be useful to identify patients at low risk of developing ESLD within a relevant time-frame, who could potentially be monitored in primary care.
Although the scoring system was derived primarily to evaluate long-term risk in PBC patients on treatment, we found that the risk scores achieved AUCs >0.90 in untreated participants. The scoring system should therefore provide accurate estimates of long-term risk prior to treatment -and then provide accurate re-evaluation of the long-term risk once treatment has been established. As such, the scoring system may be used to quantify risk-reduction and the treatment benefit derived from first-line therapy. However, our untreated validation cohort was comparatively small and this observation should be interpreted with care. To show readers how the scoring system might be 
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We anticipate that some clinicians may call for specific risk thresholds to simplify clinical decisionmaking. This is beyond the scope of the current study. There is no consensus in the literature on (a) how many risk groups should be created, and (b) where (and why) to position the cut-points.
Developing sensible guidance for choosing risk groups remains a topic for further research (21).
Furthermore, we emphasise that risk must be contextualised. Consider a patient in whom the 15-year risk score is 20%. This level of risk would be unacceptable for a 35-year old with no comorbidities -but it might be acceptable for a 70-year old with another life-shortening disease.
Treatment targets should therefore be determined by the cost-effectiveness of the treatment; its side-effect profile, and the extent to which the individual patient would benefit from the riskreduction.
The UK-PBC Research Cohort consists of thousands of patients recruited from general as well as specialist centres across the entire UK. For this reason, we believe that the cohort is highly
representative. The scoring system should therefore be widely applicable.
However, we acknowledge certain limitations. The model includes measurements at baseline and after 12 months of treatment. We do not anticipate a substantial change in the platelet count or serum albumin after 12 months of treatment with UDCA and for this reason, we consider all the measurements in the model to represent a single point in the course of the patient's disease. The strong fit of the final model in treated and untreated participants supports this assumption, although we did not specifically test the assumption in the current study. We are in the process of capturing additional data that will enable us to model liver-related outcomes using sets of variables measured at different time-points before and after starting treatment. These data will also enable us to develop of models incorporating repeated measurements. Participants in the UK-PBC Research
Cohort may be taking a sub-optimal dose of UDCA. This could potentially bias the study, if UDCA has dose-dependent, beneficial effects over-and-above those measured by the liver biochemistry on treatment. However, survival rates in the UK-PBC Research Cohort were comparable to those of additional data on these outcomes we will be able to specifically address these questions. The risk scores were derived using the variable TA instead of ALT or AST. However, we have shown that they perform equally well when just the ALT is used for TA, or just the AST. The underlying model uses the platelet count as a crude measure of disease stage. This is advantageous because the platelet count is readily available. However, more-accurate and dynamic measures of liver fibrosis such as transient elastography may be preferable. This would be especially true if anti-fibrotic therapies were available, when it would be important to quantify reduction in fibrosis.
In conclusion, we developed and validated the UK-PBC risk scores to assess the prognosis of patients with PBC using readily available and objective clinical measures. The scoring system has some advantages compared with previous prognostic models. Application of the scoring system in clinical practice may guide management and improve the distribution of health-care resources related to PBC. However, external validation of the scoring system in cohorts of treated and untreated patients is a pre-requisite to its application in clinical practice, and the scoring system should be updated as the size and characterization of the UK-PBC Research Cohort increases with time.
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Page 31 In the upper plot, the vertical line indicates the optimal dose of UDCA, 13 mg/kg/day. Note that the median dose of UDCA was approximately 12 mg/kg/day. In the lower plot, the vertical line represents 3xULN, which is the cut-off for ALP in the Paris I criteria for treatment response. Note that the vast majority of participants in this sub-group have achieved a good treatment response defined by the Paris I criteria, i.e. bilirubin ≤1xULN, ALT <2xULN and ALP<3xULN. The range of values for the 15-year risk score in Paris I non-responders (red circles) and Paris I responders (blue circles) in the current UK-PBC Research Cohort. Note that some "low-risk" responders have the same 15-year risk score as "high risk" nonresponders. For example, the arrow points to Patient A, a "low-risk" responder whose estimated 15-year risk is >40%. This patient has near-normal bilirubin, ALT and ALP but her albumin is 28 and her platelet count is 87, reflecting splenomegaly of 16.5cm. The estimated absolute risk is therefore plausible. Note also that the estimated 15-year risk in non-responders ranges from <5% to 100%. Estimating the absolute risk may assist physicians with clinical decision making; it may also help patients to plan their futures. 
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